Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$273.64 USD

273.64
414,460

-6.68 (-2.38%)

Updated May 16, 2024 03:52 PM ET

After-Market: $273.57 -0.07 (-0.03%) 4:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Here's Why You Should Retain Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.

What's in Store for Cooper Companies (COO) in Q4 Earnings?

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Align Technology (ALGN) Up 14% Since Last Earnings Report: Can It Continue?

Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN), led by its strong global presence.

CNMD or ALGN: Which Is the Better Value Stock Right Now?

CNMD vs. ALGN: Which Stock Is the Better Value Option?

Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up

Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.

Compared to Estimates, Align Technology (ALGN) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Align Technology (ALGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Align Technology (ALGN) Lags Q3 Earnings and Revenue Estimates

Align Technology (ALGN) delivered earnings and revenue surprises of -5.31% and 3.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align (ALGN) Gains From New Launches, Strategic Partnerships

Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.

Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?

Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

STERIS' (STE) Improved Volume, New Buyouts Drive Growth

On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.

PetMeds (PETS) to Advance Pet Care With New Collaboration

PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.

Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft

Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.

Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?

Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.